Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress
DALLAS, Dec. 1, 2023 /PRNewswire/ -- Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Francesco Bandello, MD, FEBO, will present at the 11th Annual FLORetina Congress taking place from November 30 - December 3, 2023 in Rome, Italy. Details for the presentation are as follows:
Title: Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients with Severe Vision Loss due to Retinitis Pigmentosa
Session: Highlighted Free Papers Innovative Therapies
In his presentation, Professor Bandello will discuss the 12-month data from Nanoscope's RESTORE Phase 2b randomized, controlled trial in patients with advanced retinitis pigmentosa.
About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases, for which no cure exists. The company's lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126 ). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress-302003205.html
SOURCE Nanoscope Therapeutics